|
Market Closed -
Nasdaq
02:30:00 04/11/2026 am IST
|
Pre-market 06:30:29 pm | |||
| 21.96 USD | +1.36% |
|
22.91 | +4.33% |
| 27/10 | Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading | MT |
| 26/10 | Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4% | MT |
| Market Cap | 272.62Cr 243.56Cr 223.73Cr 203.19Cr 381.57Cr 26TCr 391.16Cr 2.67TCr 1.07TCr 14TCr 1.02TCr 1TCr 43TCr | P/E 2026 * |
-9.78x | P/E 2027 * | -10x |
|---|---|---|---|---|---|
| Enterprise Value | 221.73Cr 198.09Cr 181.96Cr 165.26Cr 310.34Cr 21TCr 318.14Cr 2.17TCr 873.74Cr 11TCr 832.26Cr 814.45Cr 35TCr | EV / Sales 2026 * |
5.14x | EV / Sales 2027 * | 4.16x |
| Free-Float |
94.05% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ZLAB | Delayed | |
CBOE
| ZLAB | Real-time | |
|
Deutsche Boerse AG
| 1ZL | Delayed | |
|
Tradegate
| 1ZL | Real-time | |
|
Börse Stuttgart
| 1ZL | Delayed | |
|
Boerse Muenchen
| 1ZL | Real-time |
Last Transcript: Zai Lab Limited
| 1 day | +4.33% | ||
| 1 week | -6.87% | ||
| Current month | -0.50% | ||
| 1 month | -9.74% | ||
| 3 months | +20.79% | ||
| 6 months | +1.95% | ||
| Current year | +24.49% |
| 1 week | 21.42 |  | 22.85 |
| 1 month | 21.42 | | 26.92 |
| Current year | 15.96 | | 27.5 |
| 1 year | 15.96 | | 27.5 |
| 3 years | 13.48 | | 44.34 |
| 5 years | 13.48 | | 102.43 |
| 10 years | 13.48 | | 193.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 61 | 01/04/2014 |
Ya jing Chen
DFI | Director of Finance/CFO | 58 | 07/07/2023 |
Rafael Amado
PSD | President | 62 | 01/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Du
CHM | Chairman | 61 | 01/04/2014 |
John Diekman
BRD | Director/Board Member | 83 | 01/01/2017 |
Peter Wirth
BRD | Director/Board Member | 75 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Exercice | Chief Financial Officer | 2,155 | 0.0002% | ||
| 19/08/26 | Sell | Chief Financial Officer | -260 | 0.0000% | ||
| 14/08/26 | Exercice | Chief Financial Officer | 2,927 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.36% | -6.87% | -17.91% | -14.62% | 272.62Cr | |
| -0.11% | +9.94% | +57.20% | +148.21% | 1,25500Cr | |
| -1.62% | -0.95% | +42.90% | +75.88% | 64TCr | |
| -0.98% | -0.14% | +34.93% | +102.23% | 51TCr | |
| +0.70% | -1.53% | +48.75% | +65.59% | 38TCr | |
| -2.49% | +2.01% | +75.38% | +39.94% | 36TCr | |
| +1.59% | +3.19% | +31.40% | +58.29% | 30TCr | |
| +1.29% | +8.85% | +10.90% | +35.21% | 29TCr | |
| -0.90% | +2.97% | +55.67% | +70.93% | 25TCr | |
| -1.68% | +5.27% | +37.21% | +105.26% | 21TCr | |
| Average | +1.63% | +1.96% | +37.64% | +68.69% | 41.88TCr | |
| Weighted average by Cap. | +1.54% | +3.89% | +46.95% | +93.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 43Cr 39Cr 35Cr 32Cr 60Cr 4.09TCr 62Cr 422.95Cr 170.14Cr 2.16TCr 162.06Cr 158.6Cr 6.84TCr | 55Cr 49Cr 45Cr 41Cr 77Cr 5.18TCr 79Cr 536.04Cr 215.64Cr 2.74TCr 205.4Cr 201Cr 8.67TCr |
| Net income | -24Cr -22Cr -20Cr -18Cr -34Cr -2.31TCr -35Cr -239.11Cr -96Cr -1.22TCr -92Cr -90Cr -3.87TCr | -22Cr -20Cr -18Cr -16Cr -31Cr -2.08TCr -32Cr -215.1Cr -87Cr -1.1TCr -82Cr -81Cr -3.48TCr |
| Net Debt | -51Cr -45Cr -42Cr -38Cr -71Cr -4.82TCr -73Cr -498.54Cr -200.55Cr -2.54TCr -191.03Cr -186.94Cr -8.07TCr | -45Cr -40Cr -37Cr -33Cr -63Cr -4.25TCr -64Cr -439.38Cr -176.75Cr -2.24TCr -168.36Cr -164.76Cr -7.11TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | $21.96 | +1.36% | 25,23,020 |
| 02/26/02 | $21.67 | -1.84% | 4,73,887 |
| 30/26/30 | $22.07 | -1.30% | 6,37,839 |
| 29/26/29 | $22.36 | -2.95% | 6,48,511 |
| 28/26/28 | $23.04 | -2.29% | 7,04,058 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZLAB Stock
Select your edition
All financial news and data tailored to specific country editions
